Looking beyond ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae: in vitro activity of the novel meropenem-vaborbactam in combination with the old fosfomycin

J Chemother. 2021 Dec;33(8):598-600. doi: 10.1080/1120009X.2021.1909939. Epub 2021 Apr 10.

Authors

Matteo Boattini¹, Gabriele Bianco¹, Marco Iannaccone¹, Alessandro Bondi¹, Rossana Cavallo¹, Cristina Costa¹

Affiliation

¹ Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy.

PMID: 33843501
DOI: 10.1080/1120009X.2021.1909939

No abstract available

Keywords: Enterobacterales; KPC; ceftazidime-avibactam resistance; fosfomycin; meropenem-vaborbactam; synergism.

MeSH terms

Anti-Bacterial Agents / administration & dosage
Anti-Bacterial Agents / pharmacology*
Azabicyclo Compounds / pharmacology
Boronic Acids / administration & dosage
Boronic Acids / pharmacology*
Ceftazidime / pharmacology
Drug Combinations
Drug Resistance, Multiple, Bacterial / genetics
Fosfomycin / administration & dosage
Fosfomycin / pharmacology*
Genes, Bacterial
Genotype
Heterocyclic Compounds, 1-Ring / administration & dosage
Heterocyclic Compounds, 1-Ring / pharmacology*
Klebsiella pneumoniae / drug effects*
Meropenem / administration & dosage
Meropenem / pharmacology*

Substances

Anti-Bacterial Agents
Azabicyclo Compounds
Boronic Acids
Drug Combinations
Heterocyclic Compounds, 1-Ring
avibactam, ceftazidime drug combination
meropenem and vaborbactam
Fosfomycin
Ceftazidime
Meropenem